Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Oncternal Therapeutics Inc ONCT

Healthcare Biotechnology

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of... see more

Add To Watchlist

Recent & Breaking News (NDAQ:ONCT)

GTx Announces Top-Line Results from Placebo-Controlled ASTRID Trial of Enobosarm in Women with Stress Urinary Incontinence

Business Wire September 21, 2018

GTx, Inc. to Participate in the Baird 2018 Global Healthcare Conference

Business Wire August 30, 2018

Recent Analysis Shows Ferroglobe, AXT, ChemoCentryx, RedHill Biopharma, GTx, and Achillion Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire August 20, 2018

GTx Provides Corporate Update and Reports Second Quarter 2018 Financial Results

Business Wire August 14, 2018

GTx Added to the Russell 3000® Index

Business Wire June 25, 2018

GTx, Inc. to Participate in the Jefferies 2018 Global Healthcare Conference

Business Wire May 31, 2018

GTx Updates Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at 2018 AUA Annual Meeting

Business Wire May 18, 2018

Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

Benzinga.com May 18, 2018

GTx Provides Corporate Update and Reports First Quarter 2018 Financial Results

Business Wire May 15, 2018

The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Benzinga.com May 13, 2018

GTx to Present Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at a Podium Presentation at 2018 AUA Annual Meeting

Business Wire April 16, 2018

Research Report Identifies Third Point Reinsurance, GTx, pdvWireless, ACM Research, Reading International, and Canadian National Railway with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire April 13, 2018

GTx Announces Early Completion of Patient Enrollment in the ASTRID Trial, a Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence

Business Wire April 9, 2018

32 Biggest Movers From Yesterday

Benzinga.com March 6, 2018

28 Stocks Moving In Monday's Mid-Day Session

Benzinga.com March 5, 2018

GTx Announced New Data Demonstrating Enobosarm’s Potential to Treat Stress Urinary Incontinence at SUFU 2018

Business Wire March 5, 2018

GTx Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence Accepted for Podium Presentation at SUFU

Business Wire February 22, 2018

35 Biggest Movers From Yesterday

Benzinga.com January 3, 2018

A Peek Into The Markets: U.S. Stock Futures Down; Mallinckrodt To Acquire Sucampo Pharmaceuticals

Benzinga.com December 26, 2017

40 Stocks Moving In Tuesday's Mid-Day Session

Benzinga.com November 21, 2017